Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. Methods In a multicenter, noninferiority trial, we randomly assigned hospitalized patients (including patients in the intensive care unit [ICU]) who had bloodstream infection to receive antibiotic treatment for 7 days or 14 days. Antibiotic selection, dosing, and route were at the discretion of the treating team. We excluded patients with severe immunosuppression, foci requiring prolonged treatment, single cultures with possible contaminants, or cultures yielding Staphylococcus aureus . The primary outcome was death from any cause by 90 days after diagnosis of the bloodstream infection, with a noninferiority margin of 4 percentage points. Research Summary Antibiotic Treatment for 7 or 14 Days for Bloodstream Infection Results Across 74 hospitals in seven countries, 3608 patients underwent randomization and were included in the intention-to-treat analysis; 1814 patients were assigned to 7 days of antibiotic treatment, and 1794 to 14 days. At enrollment, 55.0% of patients were in the ICU and 45.0% were on hospital wards. Infections were acquired in the community (75.4%), hospital wards (13.4%) and ICUs (11.2%). Bacteremia most commonly originated from the urinary tract (42.2%), abdomen (18.8%), lung (13.0%), vascular catheters (6.3%), and skin or soft tissue (5.2%). By 90 days, 261 patients (14.5%) receiving antibiotics for 7 days had died and 286 patients (16.1%) receiving antibiotics for 14 days had died (difference, −1.6 percentage points [95.7% confidence interval {CI}, −4.0 to 0.8]), which showed the noninferiority of the shorter treatment duration. Patients were treated for longer than the assigned duration in 23.1% of the patients in the 7-day group and in 10.7% of the patients in the 14-day group. A per-protocol analysis also showed noninferiority (difference, −2.0 percentage points [95% CI, −4.5 to 0.6]). These findings were generally consistent across secondary clinical outcomes and across prespecified subgroups defined according to patient, pathogen, and syndrome characteristics. Conclusions Among hospitalized patients with bloodstream infection, antibiotic treatment for 7 days was noninferior to treatment for 14 days. (Funded by the Canadian Institutes of Health Research and others; BALANCE ClinicalTrials.gov number, NCT03005145 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Biomarker-guided strategies, randomized trials of bloodstream infection duration, and recent meta-analyses have shown that less antibiotic exposure can be appropriate in selected patients when clinical stability and source control are present (24–29).”
From Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis (2026) · cites this paper as [26]
Citations
Cites
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Ikuta, K. S., Swetschinski, L. R., Robles Aguilar, G., Sharara, F., Mestrovic, T., Gray, A. P., Davis Weaver, N., Wool, E. E., Han, C., Gershberg Hayoon, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02185-7 · Cited by 2,235
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Chastre, J., Wolff, M., Fagon, J.-Y., Chevret, S., Thomas, F., Wermert, D., Clementi, E., Gonzalez, J., Jusserand, D., Asfar, P., et al. (2003) · JAMA · doi:10.1001/jama.290.19.2588 · Cited by 1,376
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
Iversen, K., Ihlemann, N., Gill, S. U., Madsen, T., Elming, H., Jensen, K. T., Bruun, N. E., Høfsten, D. E., Fursted, K., Christensen, J. J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1808312 · Cited by 824
Association of adverse events with antibiotic use in hospitalized patients.
Tamma, P. D., Avdic, E., Li, D. X., Dzintars, K., & Cosgrove, S. E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1938 · Cited by 800
Goto, M., & Al-Hasan, M. N. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12195 · Cited by 752
Trial of short-course antimicrobial therapy for intraabdominal infection.
Sawyer, R. G., Claridge, J. A., Nathens, A. B., Rotstein, O. D., Duane, T. M., Evans, H. L., Cook, C. H., O’Neill, P. J., Mazuski, J. E., Askari, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411162 · Cited by 747
Paul, M., Shani, V., Muchtar, E., Kariv, G., Robenshtok, E., & Leibovici, L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00627-10 · Cited by 724
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson, D., Aaron, S. D., Guyatt, G., & Hébert, P. (2002) · BMJ · doi:10.1136/bmj.325.7365.652 · Cited by 708
Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difficile Infection
Stevens, V., Dumyati, G., Fine, L. S., Fisher, S. G., & van Wijngaarden, E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir301 · Cited by 446
Yahav, D., Franceschini, E., Koppel, F., Turjeman, A., Babich, T., Bitterman, R., Neuberger, A., Ghanem-Zoubi, N., Santoro, A., Eliakim-Raz, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1054 · Cited by 433
Uranga, A., España, P. P., Bilbao, A., Quintana, J. M., Arriaga, I., Intxausti, M., Lobo, J. L., Tomás, L., Camino, J., Nuñez, J., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3633 · Cited by 290
The antibiotic course has had its day
Llewelyn, M. J., Fitzpatrick, J. M., Darwin, E., SarahTonkin-Crine, Gorton, C., Paul, J., Peto, T. E. A., Yardley, L., Hopkins, S., & Walker, A. S. (2017) · BMJ · doi:10.1136/bmj.j3418 · Cited by 269
von Dach, E., Albrich, W. C., Brunel, A.-S., Prendki, V., Cuvelier, C., Flury, D., Gayet-Ageron, A., Huttner, B., Kohler, P., Lemmenmeier, E., et al. (2020) · JAMA · doi:10.1001/jama.2020.6348 · Cited by 259
Comparison of Short-Course (5 Days) and Standard (10 Days) Treatment for Uncomplicated Cellulitis
Hepburn, M. J., Dooley, D. P., Skidmore, P. J., Ellis, M. W., Starnes, W. F., & Hasewinkle, W. C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1669 · Cited by 240
Sandberg, T., Skoog, G., Hermansson, A. B., Kahlmeter, G., Kuylenstierna, N., Lannergård, A., Otto, G., Settergren, B., & Ekman, G. S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60608-4 · Cited by 189
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Havey, T. C., Fowler, R. A., & Daneman, N. (2011) · Critical Care · doi:10.1186/cc10545 · Cited by 187
Dutch Guideline for Preventing Nosocomial Transmission of Highly Resistant Microorganisms (HRMO)
Kluytmans–VandenBergh, M. F. Q., Kluytmans, J. A. J. W., & Voss, A. (2005) · Infection · doi:10.1007/s15010-005-5079-z · Cited by 163
Verway, M. J., Brown, K. A., Marchand‐Austin, A., Diong, C. C., Lee, S. M., Langford, B. J., Schwartz, K. L., MacFadden, D. R., Patel, S. N., Sander, B., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.02429-21 · Cited by 152
Molina, J., Montero-Mateos, E., Praena-Segovia, J., León-Jiménez, E., Natera, C., López-Cortés, L. E., Valiente, L., Rosso-Fernández, C. M., Herrero, M., Aller-García, A. I., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.001 · Cited by 147
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
Holland, T. L., Cosgrove, S. E., Doernberg, S. B., Jenkins, T. C., Turner, N. A., Boucher, H. W., Pavlov, O., Titov, I., Kosulnykov, S., Atanasov, B., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300220 · Cited by 115
How to Use a Noninferiority Trial: Users' Guides to the Medical Literature
Mulla, S. M., Scott, I. A., Jackevicius, C. A., You, J. J., & Guyatt, G. H. (2012) · JAMA · doi:10.1001/2012.jama.11235 · Cited by 96
Daneman, N., Shore, K., Pinto, R. L., & Fowler, R. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.07.016 · Cited by 57
on behalf of the Canadian Critical Care Trials Group, Daneman, N., Rishu, A. H., Pinto, R., Aslanian, P., Bagshaw, S. M., Carignan, A., Charbonney, E., Coburn, B., Cook, D. J., et al. (2018) · Trials · doi:10.1186/s13063-018-2474-1 · Cited by 56
Duration of Antimicrobial Treatment for Bacteremia in Canadian Critically Ill Patients*
Daneman, N., Rishu, A. H., Xiong, W., Bagshaw, S. M., Dodek, P., Hall, R., Kumar, A., Lamontagne, F., Lauzier, F., Marshall, J., et al. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001393 · Cited by 47
Pong, S., Urner, M., Fowler, R. A., Mitsakakis, N., Seto, W., Hutchison, J. S., Science, M., & Daneman, N. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044480 · Cited by 35 · cited 2×
“13,14,22,23,30,31 This trial was underpowered to assess whether prolonged treatment conferred a potential benefit in some of the smaller subgroups of patients.”
Daneman, N., Rishu, A. H., Pinto, R. L., Arabi, Y. M., Cook, D. J., Hall, R., McGuinness, S., Muscedere, J., Parke, R. L., Reynolds, S., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038300 · Cited by 30
Duration of therapy recommended for bacteraemic illness varies widely amongst clinicians
Alwan, M., Davis, J. S., Daneman, N., Fowler, R., Shehabi, Y., & Rogers, B. A. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.05.011 · Cited by 20
on behalf of the Canadian Critical Care Trials Group, Daneman, N., Rishu, A. H., Pinto, R. L., Arabi, Y. M., Belley‐Côté, E. P., Cirone, R., Downing, M., Cook, D. J., Hall, R., et al. (2020) · Trials · doi:10.1186/s13063-019-4033-9 · Cited by 14
Thaden, J. T., Tamma, P. D., Pan, Q., Doi, Y., & Daneman, N. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac005 · Cited by 13
Antimicrobial cost savings associated with shorter duration treatment for bloodstream infections
Daneman, N., Rishu, A. H., Xiong, W. G., Palmay, L., & Fowler, R. (2017) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi.1.2.04 · Cited by 8
Cited by
Singer, M., Angus, D., Annane, D., Bauer, M. W., Kalil, A. C., Klompas, M., Machado, F. R., Martin, G. S., Randolph, A. G., Shankar‐Hari, M., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02422-5 · Cited by 82
Lee, T. C., Prosty, C. J., Fralick, M., Huttner, A., McDonald, E. G., Molina, J., Paul, M., Pinto, R., Rishu, A., von Dach, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.1421 · Cited by 30
Antibiotic therapy for severe bacterial infections
Timsit, J., Ling, L., de Montmollin, É., Bracht, H., Morris, A. C., Bus, L. D., Falcone, M., Harris, P. N. A., Machado, F. R., Paiva, J.-A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08063-0 · Cited by 47
Marıno, A., Augello, E., Bellanca, C. M., Cosentino, F., Stracquadanio, S., Via, L. L., Maniaci, A., Spampinato, S., Fadda, P., Cantarella, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146905 · Cited by 33
Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection
Gilboa, M., Regev‐Yochay, G., Meltzer, E., Cohen, I., Peretz, Y., Zilberman‐Daniels, T., Segev, A., Amit, S., Yahav, D., & Barda, N. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.25252 · Cited by 27
Metadata
- Authors
- The BALANCE Investigators
- Corresponding author
- The BALANCE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-13
- Volume
- 392
- Issue
- 11
- Pages
- 1065-1078
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404539334
- Cited by
- 158
- References
- 33
- Citations by year
- 2026: 80 · 2025: 76
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- New Zealand Health Research Council
- Canadian Institutes of Health Research
- Physicians Services Incorporated Ontario
- Australian National Health Medical Research Council
- Physicians Services, by the Ontario Ministry of Health Alternate Funding Plan Innovation Fund
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- bloodstream infection, bacteremia, antibiotic duration, non-inferiority, mortality, intensive care unit patients, community-acquired infections, urinary tract infection
- MeSH terms
- Duration of Therapy, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Cross Infection, Drug Administration Schedule, Female, Humans, Intensive Care Units, Male, Middle Aged, Time Factors, Bacteremia, Treatment Outcome, Community-Acquired Infections, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.